Literature DB >> 8066072

Mutations of the p53 gene are not detectable in human testicular tumors.

M Fleischhacker1, T Strohmeyer, Y Imai, D J Slamon, H P Koeffler.   

Abstract

The tumor suppressor gene p53 is the most frequently mutated gene in human cancer. We have used polymerase chain reaction-single-strand conformation polymorphism analysis and sequencing to examine the status of the p53 gene in human testicular cancers of various histologies. We were unable to find in 40 samples and four cell lines any mutations in the regions of this gene (exons 5 through 8) that are usually mutated in other cancers. Northern blot analysis showed expression of this gene in most of the samples analyzed, as well as in four human testicular tumor cell lines. The MDM-2 gene is amplified and overexpressed in sarcomas; it binds and functionally inactivates p53. The 44 testicular tumor samples and cell lines were examined for amplification of MDM-2 by dot-blot analysis; none was found. The proto-oncogene c-kit probably plays an important role in normal testicular development. Mutation of the tyrosine phosphorylation site of a closely related member of this family of tyrosine kinase receptors (c-fms) is associated with cellular transformation and cancer. Codon 936 is the analogous tyrosine of c-kit; using polymerase chain reaction-single-strand conformation polymorphism analyses, we were unable to detect mutations at this site in our 44 testicular cancer samples. We conclude from our studies that mutations in the most conserved region of the p53 gene, as well as at codon 936 of the c-kit gene and amplification of MDM-2, are extremely rare in human testicular cancers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8066072

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells.

Authors:  D B Zamble; T Jacks; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 2.  Molecular biology of testicular germ cell tumors: current status.

Authors:  B Schmidt; R Ackermann; T Strohmeyer
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

3.  Germ cell tumors of the testis overexpress wild-type p53.

Authors:  L Guillou; A Estreicher; P Chaubert; J Hurlimann; A M Kurt; G Metthez; R Iggo; A C Gray; P Jichlinski; H J Leisinger; J Benhattar
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

4.  p53 antibodies in the serum of patients with prostate cancer.

Authors:  Yoko Kubota; Yoshiki Onmura; Hiroshi Ohji; Takuya Kunii; Tomohiro Shibasaki; Teruhiro Nakada; Yoshihiko Tomita
Journal:  Int Urol Nephrol       Date:  2007-07-06       Impact factor: 2.370

Review 5.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

6.  Lack of mutation in tumour-suppressor gene p53 in gestational trophoblastic tumours.

Authors:  Y F Shi; X Xie; C L Zhao; D F Ye; S M Lu; J J Hor; C C Pao
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

Review 7.  Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis.

Authors:  Sigrid Marie Kraggerud; Christina E Hoei-Hansen; Sharmini Alagaratnam; Rolf I Skotheim; Vera M Abeler; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Endocr Rev       Date:  2013-04-10       Impact factor: 19.871

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.